title: BioMarin Pharmaceutical
id: 4136144
BioMarin Pharmaceutical Inc is an American biotechnology company headquartered in San Rafael California It has offices and facilities in the United States South America Asia and Europe BioMarin s core business and research is in enzyme replacement therapies ERTs BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I MPS I by manufacturing laronidase Aldurazyme commercialized by Genzyme Corporation BioMarin was also the first company to provide therapeutics for phenylketonuria PKU br Over the years BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials br br br History br BioMarin was founded in by Christopher Starr Ph D and Grant W Denison Jr with an investment of a million from Glyko Biomedical and went public in Seed investors were amongst others MPM Bioventures Grosvenor Fund and Florian Sch nharting br br br Business development br In BioMarin acquired Glyko Biomedical br In BioMarin acquired Huxley Pharmaceuticals Inc Huxley which had rights to a proprietary form of diaminopyridine DAP amifampridine phosphate In BioMarin was granted marketing approval by the European Commission for diaminopyridine DAP amifampridine phosphate for the treatment of the rare autoimmune disease Lambert Eaton myasthenic syndrome LEMS BioMarin launched the product under the name Firdapse br In BioMarin acquired LEAD Therapeutics Inc LEAD a small private drug discovery and early stage development company with key compound LT an orally available poly ADP ribose polymerase PARP inhibitor studied for the treatment of patients with rare genetically defined cancers This acquisition was followed by the purchase of ZyStor Therapeutics Inc ZyStor a privately held biotechnology company developing ERTs for the treatment of lysosomal storage disorders and its lead product candidate ZC a fusion of insulin like growth factor and alpha glucosidase IGF GAA in development for Pompe disease At its R D day in October BioMarin also announced a new program for a peptide therapeutic vosoritide BMN for the treatment of achondroplasia br In BioMarin acquired Zacharon Pharmaceuticals a private biotechnology company based in San Diego focused on developing small molecules targeting pathways of glycan metabolism br In BioMarin acquired a histone deacetylase inhibitor chemical library from Repligen for million with the intention of advancing work toward therapies for Friedreich s ataxia and other neurological disorders br In November the company agreed to the acquisition of Prosensa for up to million however the range of treatments for Duchenne muscular dystrophy failed to attain FDA approval and development ceased in May br In October it was revealed that the group will open an office in Dublin to support further growth through Europe the Middle East and Asia br br br Acquisition history br The following is an illustration of the company s major mergers and acquisitions and historical predecessors this is not a comprehensive list br br br Products br As of BioMarin has six products on the market each of which is an orphan drug br br Tetrahydrobiopterin branded as Kuvan sapropterin dihydrochloride a small molecule drug for phenylketonuria introduced in as the first medication based intervention to treat phenylketonuria br Arylsulfatase B branded as Naglazyme galsulfase a recombinant protein therapeutic for Maroteaux Lamy syndrome also called mucopolysaccharidosis type VI br Iduronidase branded as Aldurazyme a recombinant protein therapeutic for mucopolysaccharidosis I br Amifampridine branded as Firdapse a small molecule drug for Lambert Eaton myasthenic syndrome as of approved in the EU only br Elosulfase alfa branded as Vimizim is the only enzyme replacement therapy to address the cause of Morquio A Syndrome MPS IVA which affects an estimated patients in the developed world The disease occurs as a result of a deficiency of activity in an enzyme involved in glycosaminoglycan GAG metabolism br Cerliponase alfa branded as Brineura is an enzyme replacement treatment for Batten disease which is a form of neuronal ceroid lipofuscinosis It was approved in br Valoctocogene roxaparvovec branded as Roctavian is an adeno associated viral vector for treatment of hemophilia A that aims to transfer a working copy of the Factor VIII gene into patients who lack one It was approved in the EU in August br Biomarin is working to develop several new drugs br br br Controversies br In BioMarin became involved in controversy surrounding diaminopyridine DAP BioMarin markets a phosphate salt of DAP under the name Firdapse In BioMarin was granted exclusive licensing rights to Firdapse for years As a result the price of a prescribed National Health Service treatment course has increased from for the unlicensed drug to for Firdapse The company states that prior to its licensing there was no guaranteed quality control of the product and no way of formally monitoring for uncommon side effects through the regulatory process br In BioMarin Pharmaceuticals was at the center of a high profile debate regarding expanded access of cancer patients to experimental drugs On the advice of her doctor Andrea Sloan a patient with advanced ovarian cancer requested that the company provide her with access to BMN an unapproved PARP inhibitor drug candidate that had exhibited promising activity in a small Phase clinical trial The company declined citing safety concerns Ms Sloan eventually received a similar drug candidate from a different company br In there was another controversy over expanded access concerning the supply of a drug on clinical trial to a German child who was suffering from a brain disorder but who was not part of the trial br In April the BBC reported that patients who took part in a trial treatment for the drug Kuvan sapropterin hydrochloride were later denied access to it The company was criticised by the NHS and Stephen Hammond MP for patient profiteering The company commented the following in response BioMarin is disappointed that the NHS England has not recognised the value of treating PKU patients with Kuvan despite more than a decade of positive patient outcomes across countries in Europe Russia and Turkey br In June a Belgian court ordered BioMarin to continue supplying Vimizim to a young girl suffering from Morquio syndrome free of charge BioMarin stopped providing free Vimizim at the beginning of the year after negotiations with Belgian health authorities regarding reimbursement of the product repeatedly failed This caused the parents to start legal proceedings to force the company to keep providing the medicine free of charge BioMarin was ordered in a preliminary injunction to keep doing so until a definitive judgment would be rendered or until the medicine would be available on the Belgian market at a reasonable price br br br br br br External links br Official website br Business data for BioMarin Pharmaceutical Inc 